A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2017 Planned End Date changed from 18 Oct 2018 to 19 Jan 2019.
- 03 Oct 2017 Planned primary completion date changed from 18 Oct 2018 to 19 Jan 2019.